What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
John W. Park focuses on Liposome, Pharmacology, Drug delivery, In vivo and Drug carrier.
His Liposome research includes themes of Immunoliposome, Glioma, Molecular biology, Targeted drug delivery and Oligonucleotide.
John W. Park has included themes like Internalization, Transplantation, Biodistribution and Doxorubicin in his Immunoliposome study.
The study incorporates disciplines such as Breast cancer, Personalized medicine and Intensive care medicine in addition to Pharmacology.
His studies in Drug delivery integrate themes in fields like Irinotecan, Enzyme inhibitor and Drug.
His Drug carrier research incorporates elements of Confocal microscopy and Therapeutic index.
His most cited work include:
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma (1220 citations)
- Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (929 citations)
- Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. (644 citations)
What are the main themes of his work throughout his whole career to date?
John W. Park mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Liposome.
His Breast cancer study combines topics from a wide range of disciplines, such as Stage, Surgery, Cancer research and Pathology.
His work deals with themes such as Clinical endpoint, Neratinib, Trastuzumab and Circulating tumor cell, which intersect with Oncology.
His Liposome study integrates concerns from other disciplines, such as Drug delivery, Drug carrier, Doxorubicin, Pharmacology and In vivo.
John W. Park combines subjects such as Immunoliposome and Biodistribution with his study of Drug delivery.
His study in Pharmacology is interdisciplinary in nature, drawing from both Brain tumor and Irinotecan.
He most often published in these fields:
- Breast cancer (32.20%)
- Internal medicine (31.78%)
- Oncology (27.54%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (31.78%)
- Oncology (27.54%)
- Circulating tumor cell (19.07%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Circulating tumor cell, Breast cancer and Cancer are his primary areas of study.
His studies deal with areas such as Cancer research, Tumor cells, Metastatic breast cancer, Molecular biology and Bone marrow as well as Circulating tumor cell.
His work on Neoadjuvant therapy as part of general Breast cancer research is frequently linked to Context, thereby connecting diverse disciplines of science.
His Cancer research is multidisciplinary, incorporating elements of Radiation therapy and Median follow-up.
His Preclinical data research is multidisciplinary, relying on both Pazopanib and Pharmacology.
His Irinotecan research is multidisciplinary, incorporating perspectives in Drug, Pharmacokinetics, Liposome and Glioma.
Between 2015 and 2021, his most popular works were:
- Adaptive Randomization of Neratinib in Early Breast Cancer (202 citations)
- Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. (109 citations)
- Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial (63 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
John W. Park mostly deals with Breast cancer, Internal medicine, Oncology, Circulating tumor cell and Biomarker.
The various areas that John W. Park examines in his Breast cancer study include Clinical endpoint, Protein kinase B and Proportional hazards model.
He interconnects Irinotecan and Estrogen in the investigation of issues within Oncology.
His Circulating tumor cell study is concerned with the field of Cancer as a whole.
His Biomarker research incorporates themes from Cancer research, Clinical trial, Trastuzumab, Metastatic breast cancer and Metastasis.
The Chemotherapy study combines topics in areas such as Glioma, Liposome and Pharmacology, Drug.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
